{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:31Z","timestamp":1792239091204,"version":"4.4.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04265-8","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:25:27Z","timestamp":1777987527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines"],"prefix":"10.1186","volume":"26","author":[{"given":"Shirin","family":"Tavakoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Samareh Salavatipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Hojjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Shamlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Kamrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Vousooghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Iranpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"6","key":"4265_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"key":"4265_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512224","author":"B Foglia","year":"2023","unstructured":"Foglia B, Turato C, Cannito S. Hepatocellular carcinoma: latest research in pathogenesis, detection and treatment. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241512224.","journal-title":"Int J Mol Sci"},{"key":"4265_CR3","doi-asserted-by":"publisher","first-page":"975408","DOI":"10.3389\/fonc.2022.975408","volume":"12","author":"Z Deng","year":"2022","unstructured":"Deng Z, et al. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Front Oncol. 2022;12:975408.","journal-title":"Front Oncol"},{"issue":"2","key":"4265_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bbadis.2017.11.026","volume":"1864","author":"P Agosti","year":"2018","unstructured":"Agosti P, Sabb\u00e0 C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):607\u201317.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"4265_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6.","journal-title":"Nat Reviews Disease Primers"},{"issue":"11","key":"4265_CR6","doi-asserted-by":"publisher","first-page":"9789","DOI":"10.3390\/curroncol30110711","volume":"30","author":"F Bicer","year":"2023","unstructured":"Bicer F, et al. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC). Curr Oncol. 2023;30(11):9789\u2013812.","journal-title":"Curr Oncol"},{"issue":"4","key":"4265_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s13402-024-00921-1","volume":"47","author":"H Zhuang","year":"2024","unstructured":"Zhuang H, et al. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma. Cell Oncol (Dordr). 2024;47(4):1205\u201320.","journal-title":"Cell Oncol (Dordr)"},{"issue":"7","key":"4265_CR8","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1007\/s00432-022-04325-2","volume":"149","author":"J Fu","year":"2023","unstructured":"Fu J, et al. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. J Cancer Res Clin Oncol. 2023;149(7):4047\u201361.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4265_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010059","author":"R Han","year":"2023","unstructured":"Han R, Wang Y, Lu L. Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics16010059.","journal-title":"Pharmaceutics"},{"issue":"5","key":"4265_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/HEP.0000000000000702","volume":"80","author":"YX Hu","year":"2024","unstructured":"Hu YX, et al. Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs. Hepatology. 2024;80(5):1058\u201373.","journal-title":"Hepatology"},{"issue":"10","key":"4265_CR11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.4251\/wjgo.v15.i10.1717","volume":"15","author":"TL Lu","year":"2023","unstructured":"Lu TL, et al. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. World J Gastrointest Oncol. 2023;15(10):1717\u201338.","journal-title":"World J Gastrointest Oncol"},{"issue":"23","key":"4265_CR12","doi-asserted-by":"publisher","first-page":"e2301983","DOI":"10.1002\/advs.202301983","volume":"10","author":"YR Hou","year":"2023","unstructured":"Hou YR, et al. The Conserved LncRNA DIO3OS Restricts Hepatocellular Carcinoma Stemness by Interfering with NONO-Mediated Nuclear Export of ZEB1 mRNA. Adv Sci (Weinh). 2023;10(23):e2301983.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"4265_CR13","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","volume":"30","author":"G Maruggi","year":"2022","unstructured":"Maruggi G, et al. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Mol Ther. 2022;30(5):1897\u2013912.","journal-title":"Mol Ther"},{"issue":"6","key":"4265_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, et al. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840\u201354.","journal-title":"Nat Biotechnol"},{"key":"4265_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, et al. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83\u2013112.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"4265_CR16","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.32604\/or.2024.043987","volume":"32","author":"S Chandra","year":"2024","unstructured":"Chandra S, et al. mRNA vaccines: a new era in vaccine development. Oncol Res. 2024;32(10):1543.","journal-title":"Oncol Res"},{"issue":"10","key":"4265_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","volume":"28","author":"A Couzinet","year":"2024","unstructured":"Couzinet A, Suzuki T, Nakatsura T. Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy. Expert Opin Ther Targets. 2024;28(10):895\u2013909.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"4265_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1039\/D2NH00289B","volume":"8","author":"S Chung","year":"2022","unstructured":"Chung S, Lee CM, Zhang M. Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases. Nanoscale Horiz. 2022;8(1):10\u201328.","journal-title":"Nanoscale Horiz"},{"issue":"4","key":"4265_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770\u201382.","journal-title":"J Hepatol"},{"issue":"1","key":"4265_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","volume":"18","author":"B Ruf","year":"2021","unstructured":"Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18(1):112\u201327.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4265_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun. 2022;13(1):758.","journal-title":"Nat Commun"},{"key":"4265_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11081357","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, et al. A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11081357.","journal-title":"Vaccines"},{"key":"4265_CR23","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3748\/wjg.v30.i19.2512","volume":"30","author":"J Urquijo-Ponce","year":"2024","unstructured":"Urquijo-Ponce J, et al. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma. World J Gastroenterol. 2024;30:2512\u201322.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4265_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","volume":"23","author":"MMP Lee","year":"2023","unstructured":"Lee MMP, Chan LL, Chan SL. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. J Liver Cancer. 2023;23(2):262\u201371.","journal-title":"J Liver Cancer"},{"key":"4265_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122662","author":"A Dyhl-Polk","year":"2021","unstructured":"Dyhl-Polk A, et al. Clinical trials of immune checkpoint inhibitors in hepatocellular carcinoma. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10122662.","journal-title":"J Clin Med"},{"key":"4265_CR26","doi-asserted-by":"publisher","first-page":"101781","DOI":"10.1016\/j.aohep.2025.101781","volume":"30","author":"L Chan","year":"2025","unstructured":"Chan L, et al. Treatment for hepatocellular carcinoma after immunotherapy. Ann Hepatol. 2025;30:101781.","journal-title":"Ann Hepatol"},{"key":"4265_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081582","author":"S Zheng","year":"2024","unstructured":"Zheng S, et al. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16081582.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4265_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Therapy. 2025;10(1):35.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"4265_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, et al. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4265_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, et al. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Therapy. 2022;7(1):329.","journal-title":"Signal Transduct Target Therapy"},{"key":"4265_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101599","author":"L Ni","year":"2023","unstructured":"Ni L. Advances in mRNA-based cancer vaccines. Vaccines (Basel). 2023. https:\/\/doi.org\/10.3390\/vaccines11101599.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"4265_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Therapy. 2024;9(1):274.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"4265_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/tcr-23-1237","volume":"13","author":"H-K Wang","year":"2024","unstructured":"Wang H-K, et al. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes. Translational Cancer Res. 2024;13(1):173.","journal-title":"Translational Cancer Res"},{"issue":"23","key":"4265_CR34","doi-asserted-by":"publisher","first-page":"2007603","DOI":"10.1002\/adma.202007603","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor\u2010associated macrophages and synergize immunotherapy against liver malignancies. Adv Mater. 2021;33(23):2007603.","journal-title":"Adv Mater"},{"issue":"3","key":"4265_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/09674845.2006.11732731","volume":"63","author":"B Peng","year":"2006","unstructured":"Peng B, et al. Induction of cytotoxic T-lymphocyte responses using dendritic cells transfected with hepatocellular carcinoma mRNA. Br J Biomed Sci. 2006;63(3):123\u20138.","journal-title":"Br J Biomed Sci"},{"issue":"1","key":"4265_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12951-025-03681-8","volume":"23","author":"Y Wu","year":"2025","unstructured":"Wu Y, et al. Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model. J Nanobiotechnol. 2025;23(1):602.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"4265_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/15321819.2022.2164507","volume":"44","author":"O Karabay","year":"2023","unstructured":"Karabay O, et al. The predictive role of NF-\u03baB-mediated pro-inflammatory cytokine expression levels in hepatitis B vaccine response. J Immunoass Immunochemistry. 2023;44(2):192\u2013203.","journal-title":"J Immunoass Immunochemistry"},{"issue":"2","key":"4265_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jgg.2021.02.006","volume":"48","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zeng J, Yan JC. mRNA vaccines. J Genet Genomics. 2021;48(2):107\u201314.","journal-title":"J Genet Genomics"},{"key":"4265_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202500110","author":"W Li","year":"2025","unstructured":"Li W, et al. Comparative function analysis of self-amplifying mRNA and self\u2010amplifying DNA. Chembiochem. 2025. https:\/\/doi.org\/10.1002\/cbic.202500110.","journal-title":"Chembiochem"},{"issue":"1","key":"4265_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12985-023-02023-0","volume":"20","author":"X Guo","year":"2023","unstructured":"Guo X, et al. Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines. Virol J. 2023;20(1):64.","journal-title":"Virol J"},{"key":"4265_CR41","doi-asserted-by":"crossref","unstructured":"SIM\u00d5ES RSDQ. Next generation of mRNA and lncRNAs based-vaccines platforms: Highlighted for HPV in head and neck squamous cell carcinoma, cervical and colorectal cancers and oncogenic viruses HBV\/HCV in hepatocellular carcinoma. Int J Biol Pharm Sci Arch. 2024;7(1):95-100.","DOI":"10.53771\/ijbpsa.2024.7.1.0027"},{"issue":"8","key":"4265_CR42","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00262-007-0448-3","volume":"57","author":"J-P Couty","year":"2008","unstructured":"Couty J-P, et al. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine. Cancer Immunol Immunother. 2008;57(8):1161\u201371.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"4265_CR43","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/vaccines11081357","volume":"11","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, et al. A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines. 2023;11(8):1357.","journal-title":"Vaccines"},{"key":"4265_CR44","first-page":"NA","volume":"10","author":"L Xing","year":"2024","unstructured":"Xing L, et al. RNA-based therapies in hepatocellular carcinoma: state of the art and clinical perspectives. Hepatoma Res. 2024;10:NA\u2013NA.","journal-title":"Hepatoma Res"},{"issue":"1","key":"4265_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.29252\/ibj.23.1.57","volume":"23","author":"Z Sharifnia","year":"2019","unstructured":"Sharifnia Z, et al. Design and development of modified mRNA encoding core antigen of hepatitis C virus: a possible application in vaccine production. Iran Biomed J. 2019;23(1):57.","journal-title":"Iran Biomed J"},{"issue":"11","key":"4265_CR46","doi-asserted-by":"publisher","first-page":"9181","DOI":"10.3390\/cimb45110576","volume":"45","author":"AN Miliotou","year":"2023","unstructured":"Miliotou AN, et al. Recruiting in vitro transcribed mRNA against cancer immunotherapy: a contemporary appraisal of the current landscape. Curr Issues Mol Biol. 2023;45(11):9181\u2013214.","journal-title":"Curr Issues Mol Biol"},{"issue":"10","key":"4265_CR47","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.4251\/wjgo.v15.i10.1717","volume":"15","author":"T-L Lu","year":"2023","unstructured":"Lu T-L, et al. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. World J Gastrointest Oncol. 2023;15(10):1717.","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"4265_CR48","doi-asserted-by":"publisher","first-page":"e01612","DOI":"10.1128\/mbio.01612-22","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen B, et al. A single dose of anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic hepatitis B virus infection. MBio. 2022;13(4):e01612-22.","journal-title":"MBio"},{"issue":"20","key":"4265_CR49","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/cells11203328","volume":"11","author":"ML Cacicedo","year":"2022","unstructured":"Cacicedo ML, Limeres MJ, Gehring S. Mrna-based approaches to treating liver diseases. Cells. 2022;11(20):3328.","journal-title":"Cells"},{"issue":"1","key":"4265_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40364-024-00644-3","volume":"12","author":"Y Gao","year":"2024","unstructured":"Gao Y, et al. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends. Biomark Res. 2024;12(1):93.","journal-title":"Biomark Res"},{"key":"4265_CR51","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S291421","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Immunotherapy of tumor RNA-loaded lipid nanoparticles against hepatocellular carcinoma. Int J Nanomed. 2021. https:\/\/doi.org\/10.2147\/IJN.S291421.","journal-title":"Int J Nanomed"},{"issue":"1","key":"4265_CR52","doi-asserted-by":"publisher","first-page":"2400217","DOI":"10.1002\/gch2.202400217","volume":"9","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Lipid Nanoparticle (LNP)-A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC). Global Challenges. 2025;9(1):2400217.","journal-title":"Global Challenges"},{"key":"4265_CR53","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S498065","author":"T Fu","year":"2024","unstructured":"Fu T, et al. Innovative dual mRNA-lipid nanoparticle therapy targeting CRHBP and CFHR3 for enhanced treatment of hepatocellular carcinoma. Int J Nanomedicine. 2024. https:\/\/doi.org\/10.2147\/IJN.S498065.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"4265_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.accounts.1c00601","volume":"55","author":"D Loughrey","year":"2021","unstructured":"Loughrey D, Dahlman JE. Non-liver mrna delivery. Acc Chem Res. 2021;55(1):13\u201323.","journal-title":"Acc Chem Res"},{"issue":"1","key":"4265_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-024-06033-6","volume":"23","author":"Q Fu","year":"2025","unstructured":"Fu Q, et al. mRNA vaccines in the context of cancer treatment: From concept to application. J translational Med. 2025;23(1):12.","journal-title":"J translational Med"},{"issue":"3","key":"4265_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.cr.7310032","volume":"16","author":"D Xia","year":"2006","unstructured":"Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res. 2006;16(3):241\u201359.","journal-title":"Cell Res"},{"key":"4265_CR57","unstructured":"Maxwell TJ. Dendritic cell mRNA delivery strategies for ovarian cancer immunotherapy. Queensland University of Technology; 2007."},{"key":"4265_CR58","unstructured":"Al Saihati HA. Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. Bahrain Med Bull, 2021. 43(4):737-746."},{"issue":"7","key":"4265_CR59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4251\/wjgo.v13.i7.673","volume":"13","author":"P Chen","year":"2021","unstructured":"Chen P, et al. Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World J Gastrointest Oncol. 2021;13(7):673.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"4265_CR60","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12967-018-1662-9","volume":"16","author":"A Petrizzo","year":"2018","unstructured":"Petrizzo A, et al. Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Translational Med. 2018;16(1):286.","journal-title":"J Translational Med"},{"key":"4265_CR61","doi-asserted-by":"publisher","first-page":"ix110","DOI":"10.1093\/annonc\/mdz438.010","volume":"30","author":"X Liu","year":"2019","unstructured":"Liu X, et al. Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution. Ann Oncol. 2019;30:ix110\u20131.","journal-title":"Ann Oncol"},{"issue":"1","key":"4265_CR62","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/hep.31279","volume":"73","author":"L Lu","year":"2021","unstructured":"Lu L, et al. Targeting neoantigens in hepatocellular carcinoma for immunotherapy: a futile strategy? Hepatology. 2021;73(1):414\u201321.","journal-title":"Hepatology"},{"key":"4265_CR63","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/S0168-8278(20)30630-9","volume":"73","author":"E Vercher","year":"2020","unstructured":"Vercher E, et al. Identification of neoantigen-reactive T cells in hepatocellular carcinoma: Implication in adoptive T cell therapy. J Hepatol. 2020;73:S39\u201340.","journal-title":"J Hepatol"},{"key":"4265_CR64","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3389\/fimmu.2019.02293","volume":"10","author":"X Li","year":"2019","unstructured":"Li X, et al. WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment. Front Immunol. 2019;10:2293.","journal-title":"Front Immunol"},{"issue":"3","key":"4265_CR65","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers17030376","volume":"17","author":"I Aggeletopoulou","year":"2025","unstructured":"Aggeletopoulou I, Pantzios S, Triantos C. Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment. Cancers. 2025;17(3):376.","journal-title":"Cancers"},{"issue":"4","key":"4265_CR66","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.3390\/ijms24043441","volume":"24","author":"D Gabbia","year":"2023","unstructured":"Gabbia D, De Martin S. Tumor mutational burden for predicting prognosis and therapy outcome of hepatocellular carcinoma. Int J Mol Sci. 2023;24(4):3441.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4265_CR67","doi-asserted-by":"publisher","first-page":"HEP39","DOI":"10.2217\/hep-2020-0034","volume":"8","author":"M Wong","year":"2021","unstructured":"Wong M, et al. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepatic Oncol. 2021;8(4):HEP39.","journal-title":"Hepatic Oncol"},{"issue":"3","key":"4265_CR68","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/SLA.0000000000006386","volume":"280","author":"CJ Wehrle","year":"2024","unstructured":"Wehrle CJ, et al. Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance. Ann Surg. 2024;280(3):504\u201313.","journal-title":"Ann Surg"},{"issue":"6","key":"4265_CR69","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/jso.25859","volume":"121","author":"H Cai","year":"2020","unstructured":"Cai H, et al. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J Surg Oncol. 2020;121(6):1007\u201314.","journal-title":"J Surg Oncol"},{"issue":"8","key":"4265_CR70","doi-asserted-by":"publisher","first-page":"11257","DOI":"10.18632\/aging.202811","volume":"13","author":"S Liu","year":"2021","unstructured":"Liu S, et al. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Aging. 2021;13(8):11257.","journal-title":"Aging"},{"issue":"12","key":"4265_CR71","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/cancers11121824","volume":"11","author":"A Mauriello","year":"2019","unstructured":"Mauriello A, et al. High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients not undergoing immunotherapy. Cancers. 2019;11(12):1824.","journal-title":"Cancers"},{"issue":"3","key":"4265_CR72","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00262-020-02711-8","volume":"70","author":"H Yang","year":"2021","unstructured":"Yang H, et al. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(3):667\u201377.","journal-title":"Cancer Immunol Immunother"},{"issue":"6533","key":"4265_CR73","doi-asserted-by":"publisher","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","volume":"371","author":"EH-C Hsiue","year":"2021","unstructured":"Hsiue EH-C, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371(6533):eabc8697.","journal-title":"Science"},{"issue":"10","key":"4265_CR74","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1136\/gutjnl-2020-322196","volume":"70","author":"T Liu","year":"2021","unstructured":"Liu T, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39\u2009+\u2009CD8+ T cells. Gut. 2021;70(10):1965\u201377.","journal-title":"Gut"},{"issue":"6","key":"4265_CR75","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747.","journal-title":"Nat Med"},{"key":"4265_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975408","author":"Z Deng","year":"2022","unstructured":"Deng Z, et al. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.975408.","journal-title":"Front Oncol"},{"key":"4265_CR77","doi-asserted-by":"publisher","first-page":"13183","DOI":"10.2147\/IJN.S498065","volume":"19","author":"T Fu","year":"2024","unstructured":"Fu T, et al. Innovative Dual mRNA-Lipid Nanoparticle Therapy Targeting CRHBP and CFHR3 for Enhanced Treatment of Hepatocellular Carcinoma. Int J Nanomed. 2024;19:13183\u201399.","journal-title":"Int J Nanomed"},{"issue":"7","key":"4265_CR78","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/0008-5472.CAN-11-2957","volume":"72","author":"S Van Lint","year":"2012","unstructured":"Van Lint S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"4265_CR79","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1038\/s41467-024-51301-0","volume":"15","author":"J Monroe","year":"2024","unstructured":"Monroe J, et al. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. Nat Commun. 2024;15(1):8119.","journal-title":"Nat Commun"},{"issue":"1","key":"4265_CR80","doi-asserted-by":"publisher","first-page":"2400217","DOI":"10.1002\/gch2.202400217","volume":"9","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Lipid Nanoparticle (LNP) -A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC). Glob Chall. 2025;9(1):2400217.","journal-title":"Glob Chall"},{"key":"4265_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050502","author":"Y Wang","year":"2025","unstructured":"Wang Y, Han R, Ling C. Unlocking mRNA vaccine potential in liver cancer treatment via synergistic bile acid modulation. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13050502.","journal-title":"Vaccines"},{"issue":"11","key":"4265_CR82","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, et al. mRNA vaccine\u2013induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Investig. 2020;130(11):5976\u201388.","journal-title":"J Clin Investig"},{"issue":"8","key":"4265_CR83","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.cell.2023.02.031","volume":"186","author":"TM Raimondo","year":"2023","unstructured":"Raimondo TM, et al. Delivering the next generation of cancer immunotherapies with RNA. Cell. 2023;186(8):1535\u201340.","journal-title":"Cell"},{"issue":"4","key":"4265_CR84","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"4265_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1246682","author":"B Wang","year":"2023","unstructured":"Wang B, et al. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1246682.","journal-title":"Front Immunol"},{"issue":"1","key":"4265_CR86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmaceutics16010059","volume":"16","author":"R Han","year":"2023","unstructured":"Han R, Wang Y, Lu L. Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment. Pharmaceutics. 2023;16(1):59.","journal-title":"Pharmaceutics"},{"issue":"6","key":"4265_CR87","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jgm.2605","volume":"14","author":"M Fotin-Mleczek","year":"2012","unstructured":"Fotin-Mleczek M, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med. 2012;14(6):428\u201339.","journal-title":"J Gene Med"},{"issue":"7823","key":"4265_CR88","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107\u201312.","journal-title":"Nature"},{"key":"4265_CR89","doi-asserted-by":"crossref","unstructured":"mRNA Vaccine Slows Melanoma Recurrence. Cancer Discov, 2023. 13(6): p. 1278.","DOI":"10.1158\/2159-8290.CD-NB2023-0028"},{"key":"4265_CR90","doi-asserted-by":"publisher","first-page":"111362","DOI":"10.1016\/j.intimp.2023.111362","volume":"127","author":"T Wei","year":"2024","unstructured":"Wei T, et al. Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice. Int Immunopharmacol. 2024;127:111362.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4265_CR91","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.ymthe.2021.04.015","volume":"29","author":"P-T Wan","year":"2021","unstructured":"Wan P-T, Ryan AJ, Seymour LW. Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther. 2021;29(5):1668\u201382.","journal-title":"Mol Ther"},{"key":"4265_CR92","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.drup.2021.100770","volume":"57","author":"L Gao","year":"2021","unstructured":"Gao L, et al. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updates. 2021;57:100770.","journal-title":"Drug Resist Updates"},{"issue":"599","key":"4265_CR93","doi-asserted-by":"publisher","first-page":"eaba9772","DOI":"10.1126\/scitranslmed.aba9772","volume":"13","author":"Y-X Lin","year":"2021","unstructured":"Lin Y-X, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med. 2021;13(599):eaba9772.","journal-title":"Sci Transl Med"},{"key":"4265_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604156","author":"S Tadic","year":"2025","unstructured":"Tadic S, et al. An RNA vaccine against adrenomedullin reduces angiogenesis and tumor burden in a syngeneic metastatic melanoma mouse model. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1604156.","journal-title":"Front Immunol"},{"key":"4265_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00467","author":"A Mougel","year":"2019","unstructured":"Mougel A, Terme M, Tanchot C. Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00467.","journal-title":"Front Immunol"},{"issue":"7","key":"4265_CR96","doi-asserted-by":"publisher","first-page":"e70417","DOI":"10.1371\/journal.pone.0070417","volume":"8","author":"SR Gameiro","year":"2013","unstructured":"Gameiro SR, et al. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013;8(7):e70417.","journal-title":"PLoS One"},{"issue":"1","key":"4265_CR97","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","volume":"11","author":"Z Pang","year":"2023","unstructured":"Pang Z, et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11(1):104.","journal-title":"Biomark Res"},{"issue":"1","key":"4265_CR98","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/v16010120","volume":"16","author":"L Wei","year":"2024","unstructured":"Wei L, et al. mRNA vaccine nanoplatforms and innate immunity. Viruses. 2024;16(1):120.","journal-title":"Viruses"},{"issue":"1","key":"4265_CR99","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29\u201332.","journal-title":"Gastroenterology"},{"issue":"12","key":"4265_CR100","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 2017;5(12):1152\u201361.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"4265_CR101","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.tips.2024.12.004","volume":"46","author":"YR Li","year":"2025","unstructured":"Li YR, et al. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci. 2025;46(2):180\u201399.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"4265_CR102","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00262-014-1558-3","volume":"63","author":"S Van Lint","year":"2014","unstructured":"Van Lint S, et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother. 2014;63(9):959\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4265_CR103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41421-024-00743-3","volume":"10","author":"R Li","year":"2025","unstructured":"Li R, et al. The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors. Cell Discov. 2025;10(1):127.","journal-title":"Cell Discov"},{"issue":"1","key":"4265_CR104","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G Zhang","year":"2023","unstructured":"Zhang G, et al. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther. 2023;8(1):365.","journal-title":"Signal Transduct Target Ther"},{"key":"4265_CR105","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang Z, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Controlled Release. 2023;360:718\u201333.","journal-title":"J Controlled Release"},{"issue":"11","key":"4265_CR106","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms22115801","volume":"22","author":"K Oura","year":"2021","unstructured":"Oura K, et al. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22(11):5801.","journal-title":"Int J Mol Sci"},{"key":"4265_CR107","doi-asserted-by":"publisher","first-page":"620688","DOI":"10.3389\/fonc.2021.620688","volume":"11","author":"D Zeng","year":"2021","unstructured":"Zeng D, et al. Immunosuppressive microenvironment revealed by immune cell landscape in pre-metastatic liver of colorectal cancer. Front Oncol. 2021;11:620688.","journal-title":"Front Oncol"},{"key":"4265_CR108","doi-asserted-by":"publisher","first-page":"874805","DOI":"10.3389\/fgene.2022.874805","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, et al. Identification of novel characteristics in TP53-mutant hepatocellular carcinoma using bioinformatics. Front Genet. 2022;13:874805.","journal-title":"Front Genet"},{"issue":"5","key":"4265_CR109","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/vaccines13050502","volume":"13","author":"Y Wang","year":"2025","unstructured":"Wang Y, Han R, Ling C. Unlocking mRNA Vaccine Potential in Liver Cancer Treatment via Synergistic Bile Acid Modulation. Vaccines. 2025;13(5):502.","journal-title":"Vaccines"},{"key":"4265_CR110","doi-asserted-by":"crossref","unstructured":"Wang J et al. Tumor-associated CD19 $^+ $ macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma. arXiv preprint arXiv:2503.17738, 2025.","DOI":"10.1038\/s41467-026-69638-z"},{"key":"4265_CR111","doi-asserted-by":"crossref","unstructured":"Liang P, et al. A first-in-human study to evaluate a personalized neoantigen-based mRNA-loaded dendritic cell vaccine, in combination with ablation, in patients with hepatocellular carcinoma. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.e14513"},{"issue":"1","key":"4265_CR112","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-021-01467-8","volume":"20","author":"Z Cai","year":"2021","unstructured":"Cai Z, et al. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer. 2021;20(1):164.","journal-title":"Mol Cancer"},{"issue":"12","key":"4265_CR113","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"7662","key":"4265_CR114","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"6382","key":"4265_CR115","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355\u201360.","journal-title":"Science"},{"key":"4265_CR116","first-page":"3","volume-title":"Vaccine Design: Methods and Protocols, Volume 3. Resources for Vaccine Development","author":"P McCaffrey","year":"2021","unstructured":"McCaffrey P. Artificial intelligence for vaccine design. In: Vaccine Design: Methods and Protocols, Volume 3. Resources for Vaccine Development. Springer; 2021. p. 3\u201313."},{"key":"4265_CR117","unstructured":"Selamoglu Z, et al. The Use and Importance of Artificial Intelligence in Vaccine Research, Development and Production. Archives of Razi Institute; 2025."},{"issue":"13","key":"4265_CR118","doi-asserted-by":"publisher","first-page":"1901989","DOI":"10.1002\/adma.201901989","volume":"32","author":"O Adir","year":"2020","unstructured":"Adir O, et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater. 2020;32(13):1901989.","journal-title":"Adv Mater"},{"key":"4265_CR119","doi-asserted-by":"publisher","first-page":"1591119","DOI":"10.3389\/fmedt.2025.1591119","volume":"7","author":"K Amoako","year":"2025","unstructured":"Amoako K, et al. Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation. Front Med Technol. 2025;7:1591119.","journal-title":"Front Med Technol"},{"key":"4265_CR120","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006334","author":"P Chen","year":"2023","unstructured":"Chen P, et al. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006334.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4265_CR121","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","volume":"54","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity. 2021;54(8):1825\u2013e18407.","journal-title":"Immunity"},{"key":"4265_CR122","doi-asserted-by":"publisher","first-page":"685126","DOI":"10.3389\/fimmu.2021.685126","volume":"12","author":"C Liu","year":"2021","unstructured":"Liu C, et al. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report. Front Immunol. 2021;12:685126.","journal-title":"Front Immunol"},{"issue":"10","key":"4265_CR123","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/cac2.12600","volume":"44","author":"DH Kim","year":"2024","unstructured":"Kim DH, et al. Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-\u03b21 (TGF-\u03b21) availability and inhibits hepatocarcinogenesis. Cancer Commun (Lond). 2024;44(10):1106\u201329.","journal-title":"Cancer Commun (Lond)"},{"issue":"12","key":"4265_CR124","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41422-025-01199-0","volume":"35","author":"H Zhao","year":"2025","unstructured":"Zhao H, et al. Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma. Cell Res. 2025;35(12):970\u201386.","journal-title":"Cell Res"},{"issue":"8","key":"4265_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401287","volume":"12","author":"J Fu","year":"2025","unstructured":"Fu J, et al. A universal strategy of anti\u2010tumor mRNA vaccine by harnessing \u201coff\u2010the\u2010shelf\u201d immunity. Adv Sci. 2025;12(8):2401287.","journal-title":"Adv Sci"},{"issue":"10","key":"4265_CR126","doi-asserted-by":"publisher","first-page":"e16836","DOI":"10.15252\/emmm.202216836","volume":"15","author":"M Wu","year":"2023","unstructured":"Wu M, et al. Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma. EMBO Mol Med. 2023;15(10):e16836.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"4265_CR127","doi-asserted-by":"publisher","first-page":"965","DOI":"10.7150\/thno.102964","volume":"15","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, et al. RNA nanotherapeutics for hepatocellular carcinoma treatment. Theranostics. 2025;15(3):965.","journal-title":"Theranostics"},{"issue":"1","key":"4265_CR128","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao H, et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. npj Vaccines. 2024;9(1):22.","journal-title":"npj Vaccines"},{"key":"4265_CR129","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163291","author":"X Lu","year":"2023","unstructured":"Lu X, et al. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI163291.","journal-title":"J Clin Invest"},{"issue":"S1","key":"4265_CR130","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1634\/theoncologist.2019-IO-S1-s01","volume":"24","author":"X Liu","year":"2019","unstructured":"Liu X, Qin S. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges. Oncologist. 2019;24(S1):S3\u201310.","journal-title":"Oncologist"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04265-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:22:17Z","timestamp":1782872537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04265-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4265"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04265-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}